Leukaemia

Leukaemia constitutes a range of cancers, typically originating in the bone marrow, and resulting in overproduction of abnormal blood cells. It is a common condition, with

...


Read more on Leukaemia

 

 

Latest news articles

Added 26 days ago Drug news

FDA approves Tibsovo to treat AML with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation.- Agios Pharma.

Agios Pharmaceuticals, Inc. has announced that Tibsovo (ivosidenib) was granted approval from the FDA for the treatment of adult patients...

Added 26 days ago Drug news

FDA approval of Tibsovo to treat AML is based on Study AG120-C-001, NCT02074839.- Agios Pharma.

The FDA approval for Tibsovo (ivosidenib) was based on the clinical data from an open-label, single-arm, multicenter dose-escalation and expansion...

Added 26 days ago Drug news

Successful Phase III study of Vyxeos compared to standard of care for AML is published in the Journal of Clinical Oncology.

Jazz Pharmaceuticals plc announced that data from the pivotal Phase III study of Vyxeos (daunorubicin and cytarabine) liposome for injection...

Search all news articles for Leukaemia
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Communicating Metastatic Breast Cancer Learning Zone

Communicating Metastatic Breast Cancer Learning Zone

This learning zone offers a short overview of the challenges faced by both healthcare professionals and patient when communicating end-stage or metastatic cancer.

Load more

Guidelines

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The prevalence of chronic myeloid leukaemia is steadily rising due to the substantial prolongation of survival that has been achieved with targeted therapy. These updated guidelines on chronic myeloid leukaemia...

Added 6 years ago

ESMO Consensus Conference on Malignant Lymphoma: General Perspectives and Recommendations for Prognostic Tools in Mature B-cell Lymphomas and Chronic Lymphocytic Leukaemia

In order to complement the already available European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with malignant lymphomas, ESMO organised a consensus conference...

Added 1 year ago

Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The estimated overall incidence of acute lymphoblastic leukaemia and lymphoblastic lymphoma in Europe is 1.28 per 1 000 000 individuals annually, with significant age-related variations.

Added 1 year ago

Search all guidelines for Leukaemia
 

Journal articles

Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.

The aim of this study was to assess the efficacy and safety of a lower dose of dasatinib (50 mg daily) in patients with newly diagnosed CML-CP.

Added 27 days ago

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Approximately 30% to 50% of adults with acute lymphoblastic leukemia (ALL) in hematologic complete remission after multiagent therapy exhibit minimal residual disease (MRD) by reverse transcriptase-polymerase chain reaction...

Added 1 month ago

Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.

Purpose: Venetoclax is an orally bioavailable B-cell lymphoma 2 inhibitor. US Food and Drug Administration and European Medicines Agency approval for patients with 17p deleted relapsed/refractory chronic lymphocytic leukemia...

Added 2 months ago

Search all journal articles for Leukaemia
 

Clinical trials

Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (CASCADE)

The purpose of this study in AML patients is to test whether vadastuximab talirine (SGN-CD33A; 33A) combined with either azacitidine or decitabine extends overall survival longer than placebo combined with either azacitidine or decitabine.

Added 1 year ago

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

The primary objective of the study is to determine whether quizartinib monotherapy prolongs overall survival (OS) compared to salvage chemotherapy in subjects with...

Added 1 month ago

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (MURANO)

The purpose of this open-label, multicenter, randomized, Phase III study is to evaluate the benefit of venetoclax in combination with rituximab compared with bendamustine in combination with rituximab...

Added 1 month ago

Search all clinical trials for Leukaemia
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.

CME

Treatment Optimisation in Chronic Lymphocytic Leukaemia

Treatment Optimisation in Chronic Lymphocytic Leukaemia
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE

Autoimmune pancytopenia following combination chemotherapy for chronic lymphocytic leukaemia

Accrediting body
BMJ Learning - British Medical Learning
Credits available
1
Registration required
1
Subscription fee
90

Personalisation of chronic lymphocytic leukaemia (CLL) care

Personalisation of chronic lymphocytic leukaemia (CLL) care
Accrediting body
Union of European Medical Specialists (via European Accreditation Council for CME)
Credits available
1
Registration required
1
Subscription fee
FREE
Search all CME for Leukaemia